Researchers Discover Deep Structural Biology Connections That Help Improve CAR Therapy

Chimeric antigen receptors (CARs) have opened up an exciting newfield of therapeutic advancements for rare and difficult-to-treat cancers, as they have the ability to deliver targeted therapies that can kill tumor cells. Peptide-centric CARs (PC-CARs) rely on specific peptide “barcodes,” which are derived from proteins within the cell created by potentially cancer-causing oncogenes, are designed to find and target cancer cells. These “barcodes” are displayed by human leukocyte antigens (HLAs), which help the immune system distinguish its own proteins from foreign invaders, like viruses.

Login Or Register To Read Full Story